Hoffmann-la Roche Inc.

Hans Lengsfeld

Paul Hadvary

Hans Steffen

Johannes Aebi

Henrietta Dehmlow

Olivier Morand

Jacques Himber

Gerard Schmid

Pierre Barbier

Pierre-Charles Wyss

Joseph Kiss

Thomas Rades

Yu-Hua Ji

Willy Schuep

Joseph Tardio

Karl Friedrich Gey

Passchier Christiaan De Smidt

Synese Jolidon

Georges Hirth

Jean-Marie Cassal

Erich Hochuli

Jacques Bailly

Ernst Kupfer

Eva-Maria Gutknecht

Hans-Peter Marki

Donald M Small

Michael Fried

G&eacute;rard Schmid

Ernst K Weibel

Syn&egrave;se Jolidon

Ku-Hua Ji

Andre Fleury

Marcel Schmid

Nigel Gains

Christine Feinle

A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.

Orlistat compositions

A pharmaceutical composition comprises at least one inhibitor of lipases, preferably an inhibitor of gastrointestinal and pancreatic lipases, such as orlistat, at least one surfactant, and at least one dispersant.

Pharmaceutical compositions containing lipase inhibitors

Method of reducing gastrointestinal side effects associated with orlistat treatment

A pharmaceutical composition contains at least one inhibitor of lipases and at least one fatty acid ester of polyol. In this composition, the fatty acid ester has a melting point above the body temperature and the polyols are chosen from the group consisting of sugars, sugar derivatives, and mixtures thereof.

Lipase inhibiting compositions

A method prevents or treats diseases associated with high plasma cholesterol levels. In addition, this method reduces plasma cholesterol levels. The method comprises administering a lipase inhibitor, e.g. orlistat, and a pharmaceutically acceptable bile acid sequestrant.

Method of treating high plasma cholesterol levels

The present invention relates to compositions containing lipase inhibitors, e.g. orlistat, and the use of such compositions for treating, reducing or preventing functional dyspepsiaafter ingestion of meals, especially of fat containing or fat rich meals.

Pharmaceutical composition and method for treatment of dyspepsia

Tertiary amines

Tertiary amines of the formula ##STR1## wherein A.sup.1, A.sup.2, A.sup.3, A.sup.4, L, M, p, T, and Q are as defined herein, have antimycotic and cholesterol-lowering activity.

The present invention provides orally administrable pharmaceutical compositions containing an inhibitor of gastrointestinal lipase, and at least one compound selected from the group consisting of chitosan, its derivatives and salts thereof. Methods are provided for preventing and treating anal leakage of oil in a patient to whom a composition containing an inhibitor of gastrointestinal lipase is orally administered.

Pharmaceutical composition containing chitosan

Aminoalkyl-substituted benzo-heterocyclic compounds of the formula ##STR1## wherein M, Q, R and T are as defined in the specification, as well as acid addition salts thereof. These compounds are useful as cholesterol level lowering agents and as antimycotic agents.

Aminoalkyl-substituted benzo-heterocyclic compounds

Steroids of the formula ##STR1## wherein R.sup.1 to R.sup.4, X and n have the significance given in the description, which lower the intestinal resorption of cholesterol and plasma cholesterol and a process of making same from corresponding steroids having an alcohol residue of the formula --O--X--OH in the 3-position.

Steroids

Novel compounds of the formula ##STR1## wherein A signifies the group ##STR2## or --(CH.sub.2).sub.5 --, which inhibit pancreas lipase and can be used for the control or prevention of obesity and hyperlipaemia, are disclosed. The inventive compounds can be produced by the cultivation of microorganism Streptomyces toxytricini, identified as NRRL 15443.

Leucine derivatives

A novel class of glucose derivatives, i.e., 3,4,6-tri-o-acyl-2-deoxy-2-nicotinamido-1-0-nicotinoyl-D-glucopyranoses are disclosed. These compounds are pharmaceutically active and are useful as plasma lypid lowering agents.

D-glucose-1-0-nicotinoyl-2-deoxy-2-nictinamido derivatives

N-nicotinoylglucosamine as a lipid level lowering agent in plasma.

Agents for lowering the lipid level in plasma

Growing community of inventors

Basel, Switzerland

Hans Lengsfeld